ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Natural Bladder Control, Go Less and Live More

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Top Vitamin and Mineral Deficiencies — Are You at Risk?

How Pomegranate May Protect Against Cancer

Omega Fix for Obesity: How the Right Fats Fight Fat

Trimming the spare tire: Canola oil may cut belly fat

The Onion: Cancer Fighter and Food Preserver

Fighting Heartburn and Gerd Naturally – And Safely!

Probiotics improve cognition in Alzheimer's patients

 
Print Page
Email Article

A Six-month, Double-blind, Placebo-controlled, Durability of Effect Study of Pregabalin for Pain Associated With Fibromyalgia

  [ 378 votes ]   [ Discuss This Article ]
By L.J. Crofford, et al. • www.ProHealth.com • November 22, 2006


Venue: Presentation Number L44, American College of Rheumatology Annual Scientific Meeting, November 10-15, 2006, Washington, DC. (http://www.rheumatology.org/annual/#2006abstracts) Authors and affiliations: L. J. Crofford, S. Simpson, J. P. Young, Jr., G. Haig, U. Sharma. University of Kentucky, Lexington, Kentucky (Crofford); Pfizer Global R&D, Ann Arbor, Michigan (Simpson, Young, Haig); MMS Holding Inc, Canton, Michigan (Sharma).

Purpose: Fibromyalgia Syndrome (FMS) affects approximately 2% to 5% of the U.S. population, and there is no FDA-approved treatment. Pregabalin is approved in the U.S. for the treatment of painful diabetic peripheral neuropathy and postherpetic neuralgia, and has demonstrated efficacy versus placebo (PBO) as monotherapy for FMS. The current study was designed to evaluate the durability of pregabalin's efficacy for relieving pain associated with FMS.

Methods: This PBO-controlled, double-blind (DB) trial consisted of a screening phase, during which patients washed out of prohibited medications; an open-label (OL) phase of 6 weeks, during which each patient's pregabalin dosage was adjusted to optimize pain control and tolerability (300, 450, or 600 mg/day); and a DB phase of 26 weeks, in which responding patients were randomized either to continue their pregabalin dosage or to PBO. Patients who had =50% reduction in mean Pain VAS score from OL baseline and scored “much improved” or “very much improved” on the Patient Global Impression of Change (PGIC) at 2 of the final 3 visits in OL were eligible for randomization into the DB phase. The primary endpoint of the double-blind phase was time to loss of therapeutic response (LTR), defined as <30% reduction in VAS pain score (from OL baseline) during 2 consecutive visits or subjective worsening of Fibromyalgia symptoms.

Results: Of the 1,051 patients who entered the OL phase, 93% were female, and 88% were white, with a mean age of 50 years, median duration of FMS of 7.8 years, and baseline mean pain VAS score of 78 (out of 100). A total of 663 patients completed OL, and 566 were randomized to DB; 279 received pregabalin (at the optimal dosage established during OL), and 287 received PBO. During the DB phase, time to LTR was significantly longer for patients treated with pregabalin compared with those receiving PBO (p<0.001). Based on Kaplan-Meier estimates of time-to-event comparing PBO patients with all pregabalin patients, 25% of PBO-treated patients lost therapeutic response by Day 7 compared with Day 34 for pregabalin-treated patients. By the end of DB treatment, nearly twice as many PBO patients (174; 61%) had lost therapeutic response compared with pregabalin-treated patients (90; 32%).

The most common adverse effects considered treatment related during OL were dizziness (36%) and somnolence (22%). In DB, the most common adverse effects that exceeded placebo were sinusitis (5% pregabalin, 3% PBO) and arthralgia and anxiety (5% pregabalin, 2% PBO). Most adverse effects were mild or moderate in intensity. There were two deaths; neither was considered treatment related.

Conclusions: Pregabalin demonstrated durability of pain relief associated with FMS by significantly delaying time to loss of therapeutic response versus placebo.




Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Ultra ATP+, Double Strength Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients
Help for Soreness and Swelling: What Do Silkworms Have to Do With It? Help for Soreness and Swelling: What Do Silkworms Have to Do With It?
Breaking Through the Mental Fog Breaking Through the Mental Fog
Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You
Block food Cravings At Their Molecular Root Block food Cravings At Their Molecular Root

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map